Hypermetabolism in the hippocampal formation of cognitively impaired patients indicates detrimental maladaptation

Ivayla Apostolova a,⁎, Catharina Lange c,⁎, Anja Mäurer d, Per Suppa e, Lothar Spies e, Michel J. Grothe f, Till Nierhaus g,⁎, Jochen B. Fiebach h, Elisabeth Steinhagen-Thiessen i, R. Buchert b,⁎, for the Alzheimer’s Disease Neuroimaging Initiative j

a Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany
b Department of Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany
c Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
d Evangelisches Geriatriezentrum Berlin, Berlin, Germany
f Jung diagnostics GmbH, Hamburg, Germany
g German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
h Center for Cognitive Neuroscience Berlin (CCNB), Department of Education and Psychology, Freie Universität Berlin, Germany
i Center for Stroke Research Berlin, Charité—Universitätsmedizin, Berlin, Germany
j Lipid Clinic at the Interdisciplinary Metabolism Center, Charité - Universitätsmedizin, Berlin, Germany

A R T I C L E  I N F O

Article history:
Received 26 July 2017
Received in revised form 27 December 2017
Accepted 7 January 2018
Available online 31 January 2018

Keywords:
Hippocampal formation
Hypermetabolism
Cognitive impairment
Dementia
Geriatric inpatients
Positron emission tomography

A B S T R A C T

Structural deterioration and volume loss of the hippocampal formation is observed in many diseases associated with memory decline. Paradoxically, glucose metabolism of the hippocampal formation can be increased at the same time. This might be a consequence of compensatory (beneficial) or maladaptive (detrimental) mechanisms. Aim of this study was to differentiate between compensation and maladaptation by analyzing the association between glucose metabolism in the hippocampal formation measured by positron emission tomography with the glucose analogue 18F-fluorodeoxyglucose and cognitive performance as characterized by the extended Consortium to Establish a Registry for Alzheimer’s Disease test battery in a sample of 87 patients (81.8 ± 5.4 years) with mild cognitive impairment or mild dementia and varying etiological diagnoses. Glucose metabolism in the hippocampal formation was negatively correlated with the performance in several cognitive subdomains, most pronounced for verbal semantic fluency, independent of overall neuronal dysfunction, presence of clinical Alzheimer’s disease, and overall cognitive performance. This finding provides evidence that increased glucose metabolism in the hippocampal formation of cognitively impaired patients indicates detrimental maladaptation rather than a beneficial compensatory reaction. Excess glucose metabolism in the hippocampal formation might be a useful therapeutic target in these patients.

© 2018 Elsevier Inc. All rights reserved.

1. Introduction

The hippocampus is a key brain region in the pathogenesis of memory dysfunction in many diseases including Alzheimer’s disease (AD) (Schröder and Pantel, 2016), frontotemporal lobar degeneration (Dermody et al., 2016), Parkinson’s disease (Gee et al., 2017), and also non-neurodegenerative diseases such as depression (den Heijer et al., 2011). Hippocampal atrophy is also observed in cerebrovascular disease (CVD), in line with selective vulnerability of the hippocampus in brain ischemia-hypoxia (Schmidt-Kastner and Freund, 1991). In AD, the hippocampus is among the first targets for tau tangle aggregates (after the transentorhinal cortex) (Braak and Braak, 1991) and shows impaired functional connectivity (Brier et al., 2012; Petrella et al., 2011; Zhang et al., 2010) and atrophy (Jack et al., 1999). Atrophy of the hippocampus and other mesiotemporal structures is a very consistent finding in AD and its prodromal stages (Chapleau et al., 2016), and therefore, it is considered a very promising biomarker to support the etiological diagnosis of AD in subjects with mild cognitive impairment (MCI; Ten Kate et al., 2017). Mental and physical training can stimulate neurogenesis in...
the hippocampus resulting in gain of hippocampal gray matter (GM) volume, detectable by magnetic resonance imaging (MRI), and improvement of memory function (DiFeo and Shors, 2017; Duzel et al., 2016).

Positron emission tomography (PET) of the brain with the glucose analogue 18F-fluorodeoxyglucose (FDG) is a well-established functional imaging modality for noninvasive in vivo assessment of brain glucose metabolism as surrogate marker of signaling-related synaptic activity (Sokoloff, 1999). Dysfunction and loss of synapses in AD results in a characteristic spatial pattern of reduced FDG uptake in the brain comprising the posterior cingulate cortex/precuneus area and parietotemporal association cortices (Minoshima et al., 1997). Other diseases present with different reduction patterns in FDG PET; which is the rationale for the use of FDG PET in the differential diagnosis of dementing diseases. FDG PET can detect the disease characteristic alterations of brain activity before cognitive decline is recognized (Terry et al., 1991).

In striking contrast to the very consistent association between mesiotemporal atrophy and memory decline, mesiotemporal FDG PET findings in patient populations with memory decline are far from being consistent. Some groups reported reduced hippocampal FDG uptake in AD (De Santi et al., 2001; Ishii et al., 1996; Mosconi et al., 2005, 2006; Nestor et al., 2003). Other authors reported rather preserved or even increased hippocampal glucose metabolism despite hippocampal atrophy and suggested compensation mechanisms to maintain function by recruiting additional neuronal resources as possible explanation (Chetelat et al., 2008; Desgranges et al., 1998; Herholz et al., 2002; Ibáñez et al., 1998; Ishii et al., 1998; Minoshima et al., 1997). A functional resting-state MRI (rs-fMRI) study by Tahmasian et al. (Tahmasian et al., 2015) using seed-based functional connectivity analysis recently revealed hippocampal glucose metabolism to be inversely correlated with the connectivity of hippocampus and precuneus. This finding supports the hippocampus disconnection hypothesis according to which uncoupling from cortical inputs might cause increased hippocampal activity (Das et al., 2013; Pasquini et al., 2015; Tahmasian et al., 2015).

There is not only ongoing discussion of quite different mechanisms that might contribute to hippocampal hyperactivity in cognitive decline but also it is even not clear whether hippocampal hyperactivity results from compensatory or maladaptive alterations (Pievani et al., 2014). Yet, compensatory mechanisms, for example, recruitment of additional neuronal resources, are expected to improve cognition, whereas maladaptation should result in further deterioration of cognitive performance compared to patients with the same level of neuropathology but hippocampal glucose metabolism decreasing in parallel with hippocampus volume. To test whether relative increase of hippocampal glucose metabolism is due to compensatory (beneficial) or maladaptive (detrimental) mechanisms, this study evaluated the association between glucose metabolism in the hippocampal formation and cognitive performance in a sample of 87 patients with MCI or mild dementia of diverse etiology hospitalized in a geriatrics unit for an acute or subacute indication (the hippocampal formation was used rather than the hippocampus because this larger region of interest better matches the spatial resolution of PET). In addition, the study assessed the relationship between glucose metabolism in the hippocampal formation and corticohippocampal connectivity as assessed by rs-fMRI using very similar analysis methods as the study by Tahmasian et al. (2015), to simplify comparison of the results. Brain FDG PET, rs-fMRI, and detailed neuropsychological testing had been performed as part of a prospective study (WHO Trials Registry DRKS000005041) (Apostolova et al., 2017; Ritter et al., 2016). This clinical patient sample was expected to cover a large range of FDC uptake in the hippocampal formation (Hippom-FDG) and, therefore, to provide adequate power to detect possible associations between glucose metabolism and cognitive performance.

2. Material and methods

2.1. Cognitively impaired patients

The sample of cognitively impaired patients was derived from the prospective clinical study “Comparison and integration of modalities in the early and differential diagnosis of dementing disorders in hospitalized geriatric patients: a prediction study” (WHO Trials Registry DRKS000005041). This investigator-initiated study has been approved by the German Federal Institute for Drugs and Medical Devices as phase III trial of FDG PET for the diagnosis of cognitive impairment (reference 61-3910-4039304; EudraCT 2013-000140-2). Ethics approval has been obtained from the ethics committee of the state of Berlin (13/0234-EK12). Monitoring was conducted both internally (by the Charité research group geriatrics) and externally (by syneed medidata GmbH, Konstanz, Germany). The main inclusion criterion of this study was clinically uncertain suspicion of AD, CVD, or mixed disease (MD, AD + CVD) as the cause of cognitive impairment (Apostolova et al., 2017; Ritter et al., 2016).

The analyses presented here included all patients who successfully completed FDG PET and structural MRI (i.e., T1-weighted magnetization prepared rapid acquisition gradient echo [MPRAGE]) and for whom an etiological diagnosis of their cognitive impairment by an interdisciplinary team of academic experts was available (n = 87, age = 81.8 ± 5.4 years, 57 females). The etiological diagnoses included non-neurodegenerative etiology (n = 15), AD (n = 17), CVD (n = 23), MD (n = 25), and neurodegenerative etiology other than AD (n = 7). The etiological diagnosis was based on patient history, physical/neurological examination, standard blood/urine laboratory tests, detailed neuropsychological testing, structural MRI, and FDG PET. The etiologic subgroups did not differ with respect to education (duration in years, analysis of variance p = 0.714). The clinical dementia rating score was 0 in 2.3% of the patients, 0.5 in 63.2%, and >0.5 in 34.5% of the included patients. Patient characteristics are summarized in Table 1. The patient sample reflects the wide spectrum of diseases associated with hippocampal alterations and cognitive impairment.

Neuropsychological testing included the German version of the test battery of the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD; Morris et al., 1988). The CERAD test battery comprised tests of verbal fluency (by naming animals), an abbreviated version of the Boston Naming Test (15 items), Mini–Mental State Examination (MMSE), word list learning/recall/ recognition, constructional praxis and recall of constructional praxis, Trail Making Test A (MTM-A), Trail Making Test B (MTM-B), and a phonemic fluency test (“S-words”) (Monsch and Kressig, 2010). All subscores were transformed to z-scores corrected for age, sex, and education based on normative samples for the German CERAD version (Ehrensperger et al., 2010).

MRI of the brain was performed with a 3T MR scanner (Siemens Trio Tim) for all patients. The structural sequences included 3-dimensional T1-weighted MPRAGE (1 × 1 × 1 mm3) and T2-weighted fluid attenuation inversion recovery (in-plane 1.2 mm, slice thickness 2.5 mm). The functional sequences included rs-fMRI based on a 2-dimensional single-shot echo-planar imaging sequence (repetition time = 2300 ms, echo time = 30 ms, x = 90°, 64 × 64 matrix, 34 slices, voxel size = 3.0 × 3.0 × 4.0 mm3, bandwidth = 2232 Hz/pixel, 1 average, segmented k-space) with 150 time points and a time resolution of 2300 ms.

Brain FDG PET was acquired with a time-of-flight PET/CT system Philips GEMINI TF 16 according to common guidelines (Varrone et al., 2009).
2.2. Cognitively normal control subjects

A sample of cognitively normal control (NC) subjects was obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). For each of the 87 cognitively impaired patients, the ADNI NC subject with closest age at the time of baseline FDG PET was selected among all ADNI NC subjects with brain MRI and FDG PET at baseline. This resulted in an age-matched sample of 87 ADNI NC subjects (80.8 ± 3.2 years, t test p = 0.160) that was used for defining normative data for hippocampal formation FDG PET signal.

Image data itself may systematically differ between the ADNI and the group of cognitively impaired patients of the present study because of scanner-specific differences in image characteristics. However, spatial resolution in the reconstructed PET images, the most important cause of interscanner differences of (attenuation- and scatter-corrected) PET images (Joshi et al., 2009), was very similar in both samples: 8-mm full-width-at-half-maximum (FWHM) in the ADNI sample (Jagust et al., 2010) and 7-mm FWHM in the sample of cognitively impaired patients (Ritter et al., 2016). In addition, this small difference was taken into account by partial volume effect (PVE) correction (subsection “PET image analysis”).

Data from the NC subjects were obtained from the ADNI database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether a combi- nation of the ADNI’s PET, MRI, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD.

2.3. PET image analysis

PET images were acquired, reconstructed, and corrected for head motion as described previously (Lange et al., 2016). Correction of PVEs was performed using the Müller-Gartner method (Müller-Gartner et al., 1992) as implemented in the PETPVE12 toolbox developed and validated by Gonzalez-Escamilla et al. (2017). The individual tissue probability maps for partial volume correction were obtained by applying the unified segmentation algorithm of the statistical parametric mapping software package (version SPM12, default parameter settings) to the individual MPRAGE MRI. PVE correction assumed spatial resolution of 8-mm and 7-mm FWHM in the ADNI sample and in the sample of cognitively impaired patients, respectively.

PVE-corrected HippForm-FDG was computed separately for the left and right hemisphere using the union of the unilateral hippocampus region of interest (ROI) and the ipsilateral para-hippocampus ROI in the anatomical space of the Montreal Neurological Institute (MNI) as defined by the Automated Anatomical Labeling (AAL) atlas (Tzourio-Mazoyer et al., 2002) implemented in the WFU PickAtlas (Maldjian et al., 2003). The inverse of the elastic transformation from patient space to MNI space generated by unified segmentation was used to transform the ROIs from MNI space to patient space for ROI analysis.

PVE-corrected HippForm-FDG was scaled to mean FDG uptake in the pons. The pons ROI of the “TD Lobes” atlas in the WFU PickAtlas was used for this purpose (after transformation to patient space; Minoshima et al., 1995). FDG uptake in the pons was not corrected for PVE because the pons mainly consists of white matter (WM) tracts and the used Müller-Gartner PVE correction algorithm is only defined for the GM of the brain (MPRAGE MRI does not allow reliable segmentation of the small GM nuclei in the pons).

The maximum over left and right hemispheres of the pons-scaled, PVE-corrected HippForm-FDG was used in the analyses presented here. The rationale for using the maximum over the left and right hippocampus (rather than the mean) was that averaging over both hemispheres dilutes the effect of hypermetabolism that is more pronounced in 1 hemisphere.

The union of the bilateral AAL-ROIs of posterior cingulate, precuneus, and inferior and superior parietal cortices was used as AD signature meta-ROI to assess pons-scaled, PVE-corrected FDG uptake in brain regions typically most affected by AD (AD-FDG).

2.4. GM volume of the hippocampal formation

GM volume of the hippocampal formation (HippForm-GM) was obtained by applying the same AAL-ROIs (HippForm-GM) to the left and right
hippocampal formation used to assess FDG uptake to the patient's GM probability map from unified segmentation (in patient space). HippForm-GM was obtained by summing the voxel intensities over all voxels of the GM tissue probability map within the ROI, as described previously (Suppa et al., 2015a,b; Wolf et al., 2017). The minimum of GM volume in the left and right hippocampal formation (HippForm-GM) was used in the analyses.

2.5. Resting-state fMRI connectivity analysis

The first 5 volumes of each rs-fMRI scan were removed to account for adaptation of the patient to scanner noise and environment. FMRIB Software Library (FSL) (http://www.fmrib.ox.ac.uk/fsl) and Analysis of Functional NeuroImages (AFNI) (http://afni.nimh.nih.gov/afni) were used for slice time correction, spike removal, head motion correction, removal of the skull, and detrending. Further analysis was performed using SPM8 (www.fil.ion.ucl.ac.uk/spm/) running under MATLAB 8.2 (The MathWorks, Inc, Natick, MA). Anatomical (T1) images were coregistered to the rs-fMRI images and segmented into GM, WM, and cerebrospinal fluid (CSF). All images (GM, WM, CSF, and rs-fMRI) were spatially normalized to the MNI152 space with the voxel size $3 \times 3 \times 3$ mm$^3$. An average of GM, WM, and CSF mask was derived from the individual segmented GM, WM, and CSF images, respectively. Smoothing with a 6-mm Gaussian kernel (FWHM) and temporal band-pass filtering (0.01–0.1 Hz) was applied to the rs-fMRI data. CompCor analysis (DPABI—toolbox for Data Processing and Analysis of Brain Imaging, http://rfmri.org/dpabi) was performed within the CSF/WM mask on the rs-fMRI data (Behzadi et al., 2007). The resulting first 5 principal components, together with 6 head motion parameters and the global mean signal (calculated within the GM mask), were used as nuisance signals to regress out associated variance.

Eigenvector centrality maps were generated within the GM mask using fast eigenvector centrality mapping (ECM) (Lohmann et al., 2010; Wink et al., 2012). ECM is a data-driven method to characterize the connectivity of a voxel within the whole brain without any prior assumption. ECM attributes a value to each voxel in the brain that is large if the voxel is strongly correlated with many other nodes that are themselves central within the network (Lohmann et al., 2010). Eigenvector centrality of an ROI such as the hippocampal formation was obtained by averaging eigenvector centrality over all voxels in the ROI.

To further analyze whole-brain functional connectivity, rs-fMRI data were parcellated into 116 ROIs according to the AAL atlas by averaging the blood oxygenation level dependent time courses of all voxels within 1 ROI. Then Pearson's correlation coefficient between any 2 ROIs was calculated.

2.6. Statistical analyses

First, HippForm-FDG, FDG uptake in the AD meta-ROI (AD-FDG), and HippForm-GM were tested for association with each of the CERAD-Plus subscores using Pearson's correlation test.

In the second step, statistically significant correlations from the first step were corrected for overall cognitive performance (MMSE z-score), AD-FDG, or clinical diagnosis of probable AD (binary score with value 1 in case of AD or MD, value 0 in case of non-neurodegenerative etiology or neurodegenerative etiology other than AD).

Third, multivariable linear regression analysis of CERAD-Plus subscores was performed with HippForm-FDG, AD-FDG, HippForm-GM, and MMSE z-score as explanatory variables (backwards, probability-of-F-to-enter $< 0.05$, probability-of-F-to-remove $> 0.10$).

Finally, HippForm-FDG was tested for correlation with the eigenvector centrality of the hippocampal formation and with the connectivity of the hippocampal formation with each AAL-ROI. Eigenvector centrality and connectivity of the hippocampal formation in the same hemisphere from which HippForm-FDG was derived was used in these analyses.

3. Results

3.1. Imaging-based markers in cognitively impaired patients

HippForm-FDG ranged between 0.71 and 1.60 (mean 1.17 ± 0.15, median 1.15), AD-FDG ranged between 1.35 and 2.83 (mean 1.95 ± 0.31, median 1.89), and HippForm-GM ranged between 2.77 and 8.12 mL (mean 5.38 ± 1.02 mL, median 5.50 mL). The differences of HippForm-FDG between etiological subgroups did not reach the level of statistical significance, neither the difference between the 5 etiological subgroups according to Table 1 (Kruskal-Wallis $p = 0.139$) nor the difference between patients with AD (either alone or with concomitant CVD) and the remaining patients ($1.15 \pm 0.18$ vs. $1.19 \pm 0.12$, t-test $p = 0.202$). In contrast, AD-FDG differed between etiological groups (Kruskal-Wallis $p < 0.0005$): in AD patients and in MD patients, it was lower compared to “non-neurodegenerative” patients and compared to CVD patients (all Mann-Whitney $p < 0.0005$). HippForm-GM also differed between etiological groups (Kruskal-Wallis $p = 0.024$): in AD patients and in MD patients, it was lower compared to “non-neurodegenerative” patients (Mann-Whitney $p = 0.009$ and 0.006, respectively). A summary of imaging-based markers stratified according to etiological subgroups is given in Table 1.

HippForm-FDG was not associated with AD-FDG ($r = 0.107$, $p = 0.322$), but it showed a moderate positive correlation with GM volume of the ipsilateral hippocampal formation ($r = 0.443$, $p < 0.0005$).

3.2. Comparison with cognitively NC subjects

Histograms of HippForm-GM and HippForm-FDG in the sample of cognitively NC subjects compared to the sample of cognitively impaired patients are shown in Fig. 1. HippForm-GM was significantly lower in the cognitively impaired patients compared to the cognitively NCs: $5.38 \pm 1.02$ mL versus $6.87 \pm 0.87$ mL ($p < 0.0005$). The difference of the variance ($1.02$ mL vs. $0.87$ mL) did not reach statistical significance (Levene test $p = 0.115$). In contrast, HippForm-FDG was not different between cognitively impaired patients and the cognitively NCs ($1.17 \pm 0.15$ vs. $1.20 \pm 0.10$, $p = 0.178$). However, the variance was significantly larger in the cognitively impaired patients ($0.15$ vs. $0.10$, $p = 0.001$). The larger variance of HippForm-FDG in the cognitively impaired patients was driven by a rather symmetric broadening of the distribution in both directions (Fig. 1) indicating that there were both cognitively impaired patients with reduced glucose metabolism in the hippocampal formation and cognitively impaired patients with increased glucose metabolism in the hippocampal formation.

3.3. Association between imaging-based markers and cognitive performance in cognitively impaired patients

There was a significant negative correlation between HippForm-FDG and the naming animals z-score ($r = -0.284$, $p = 0.008$) and the S-words z-score ($r = -0.264$, $p = 0.015$) of the CERAD-Plus test battery (Figs. 2 and 3). MRI and PET images of a representative patient are shown in Fig. 4.

Replacing maximum HippForm-FDG of both hemispheres by the mean of both hemispheres resulted in slightly weaker and slightly less significant correlations: the Pearson correlation coefficient between HippForm-FDG and the naming animals z-score changed...
The subsample of patients with AD (n = 42, r = 0.302, p = 0.004, Fig. 2); HippForm–GM was positively correlated with MMSE (r = 0.227, p = 0.034), word list learning (r = 0.272, p = 0.011), word list recall (r = 0.445, p < 0.0005), and figures recall (r = 0.230, p = 0.035). The positive correlation between AD-FDG and the naming animals z-score observed in the whole sample was not confirmed in the subsample of patients with AD (n = 42, r = 0.065, p = 0.688) nor in the subsample of patients without AD (n = 45, r = 0.151, p = 0.321). Thus, the correlation in the whole sample was mainly driven by differences between patients with and without AD. This is also evident from the scatter plots in Fig. 3 (top row, middle panel): the scatter plot of patients with AD is shifted to bottom left relative to the scatter plot of patients without AD.

The association between HippForm–FDG and the CERAD-Plus animals z-score was confirmed (Table 2) by the partial correlation analyses that corrected for MMSE (partial correlation coefficient between HippForm–FDG and the naming animals z-score r = −0.297, p = 0.006), for AD-FDG (r = −0.334, p = 0.002), or for presence versus absence of clinical AD (r = −0.321, p = 0.003). The negative correlation between HippForm–FDG and the naming animals z-score also remained significant after correction for GM volume of the ipsilateral hippocampal formation (partial correlation coefficient = −0.333, p = 0.002).

Linear regression of the CERAD-Plus animals z-score with HippForm–FDG, AD-FDG, HippForm–GM, and MMSE z-score as explanatory variables included only HippForm–FDG (beta = −0.308, p = 0.003) and the MMSE z-score (beta = −0.382, p = 0.0005) in the final model. AD-FDG (beta = 0.143, p = 0.148) and HippForm–GM (beta = 0.085, p = 0.409) were excluded.

To test for potential impact of the reference region used for scaling of the PET intensity, the correlation analyses were repeated with the cerebellum as PET reference region (instead of the pons). There was a strong correlation between PVE-corrected HippForm–FDG scaled to pons (maximum of both hemispheres) and PVE-corrected HippForm–FDG scaled to cerebellum (maximum of both hemispheres, Pearson correlation coefficient r = 0.862, p < 0.0005). In line with this, the results with the cerebellum as reference region confirmed the results with pons scaling. For example, PVE-corrected HippForm–FDG (maximum of both hemispheres) scaled to the cerebellum also showed a significant negative correlation with the naming animals z-score of the CERAD-Plus test battery (r = −0.299, p = 0.005). This suggests that the negative correlation between glucose metabolism in the hippocampal formation and verbal semantic fluency is not a scaling artifact. Intensity scaling of FDG PET is not required when the absolute local metabolic rate of glucose is determined (in nmol glucose per 100g of tissue per minute). This, however, requires sampling of arterial blood (or arterialized venous blood) starting at the time of FDG administration until the end of the PET scan for computation of the arterial input function for tracer kinetic modeling. Blood sampling during PET had not been performed in the hospitalized geriatric patient sample of this study.

3.4. Association between metabolic activity and connectivity of the hippocampal formation in cognitively impaired patients

Eigenvector centrality of the hippocampal formation (with maximum FDG uptake of left and right hemisphere) was 0.00411 ± 0.00004. It was not correlated with HippForm–FDG (r = −0.087, p = 0.436). HippForm–FDG was also not correlated with functional connectivity of the hippocampal formation (with maximum FDG uptake) with any other AAL-ROI, including the ipsilateral precuneus (r = 0.064, p = 0.569) and the ipsilateral posterior cingulate cortex (r = −0.096, p = 0.393).

Eigenvector centrality of the hippocampal formation (with maximum FDG uptake of left and right hemisphere) was lower in patients with AD (either alone or with concomitant CVD) compared to patients without AD (0.00410 ± 0.00005 vs. 0.00413 ± 0.00003, t test p = 0.011).

4. Discussion

Volume loss of the mesiotemporal lobe is the strongest macrostructural correlate of memory decline in many diseases. In
Fig. 2. Pearson coefficient of the correlation between the performance in the different CERAD subdomains (z-scores adjusted for age, gender and education) and pons-scaled, PVE-corrected FDG uptake in the hippocampal formation (HippForm-FDG, maximum of both hemispheres, red), pons-scaled, PVE-corrected FDG uptake in the bilateral AD meta-ROI (AD-FDG, green), and gray matter volume in the hippocampal formation (HippForm-GM, minimum of both hemispheres, blue), * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.0005, ▲ p < 0.10. Abbreviations: AD, Alzheimer’s disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; 18F-FDG, fluorodeoxyglucose; PVE, partial volume effect; ROI, region of interest. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Fig. 3. Scatter plots of the age-, gender-, and education-adjusted z-score of the animals (top) and the word list recall (bottom) subtest of the CERAD test battery versus pons-scaled, PVE-corrected FDG uptake in the hippocampal formation (HippForm-FDG, maximum of both hemispheres, left column), pons-scaled, PVE-corrected FDG uptake in the bilateral AD meta-ROI (AD-FDG, middle column), and gray matter volume in the hippocampal formation (HippForm-GM, minimum of both hemispheres, right column). Filled symbol: patients with clinical AD, either alone or with concomitant cerebrovascular disease; Open symbol: cases without clinical AD; and Dashed line: linear regression. Abbreviations: AD, Alzheimer’s disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; 18F-FDG, fluorodeoxyglucose; PVE, partial volume effect; ROI, region of interest.
contrast, glucose metabolism in the mesiotemporal lobe can be relatively preserved or even increased also at advanced disease stages (Chetelat et al., 2008; Ishii et al., 1998; Tahmasian et al., 2015). Possible explanations include compensatory (beneficial) recruitment of additional neuronal resources (Chetelat et al., 2008) and maladaptive overactivity (“running hot”) of internal hippocampal circuitry (Bakker et al., 2012; Das et al., 2013; Salami et al., 2014; Tahmasian et al., 2015). In the first case (beneficial compensation), hippocampal glucose metabolism is expected to be positively correlated with cognitive performance. In the latter case (maladaptive overactivity) the correlation is expected to be negative.

The main finding of the present study is the negative correlation between glucose metabolism in the hippocampal formation and cognitive performance in several domains in cognitively impaired patients, that is, higher glucose metabolism in the hippocampal formation was associated with poorer cognitive performance. This suggests that increased glucose metabolism in the hippocampal formation of cognitively impaired patients is a consequence of detrimental adaption rather than a beneficial compensatory reaction. The association between higher glucose metabolism in the hippocampal formation and lower CERAD-Plus scores was most significant statistically for the naming animals subscore. In the naming animals test, subjects are asked to name as many animals as possible in 60 seconds. The performance in this test depends on language, verbal productivity, semantic memory, and cognitive flexibility. The association between higher glucose metabolism in the hippocampal formation and lower verbal semantic fluency was independent of the magnitude of overall neuronal dysfunction/degeneration as measured by hypometabolism in AD characteristic brain regions (Table 2). It was also independent of the presence (vs. absence) of clinical Alzheimer’s disease (Table 2, Fig. 3). This suggests that the association between higher glucose metabolism in the hippocampal formation and lower verbal semantic fluency is not specific for AD (similar to the association between mesiotemporal atrophy and memory performance i.e., also not specific for AD). In line with this, glucose metabolism in the hippocampal formation did not differ between the different etiological subgroups of cognitively impaired patients. Finally, the association was also independent of overall cognitive performance (MMSE), indicating that it is specific for verbal semantic fluency to some extent. This is in line with the well-documented role of hippocampal integrity for verbal semantic fluency (Baldo et al., 2006; Gleissner and Elger, 2001; Glikmann-Johnston et al., 2015).

PVE-corrected HippForm-FDG was significantly correlated with its GM volume ($r = 0.443, p < 0.005$). Thus, it might not be excluded a priori that the observed negative correlation between PVE-corrected HippForm-FDG and the CERAD-Plus animals $z$-score was driven by GM volume, for example, due to incomplete correction or overcorrection of PVEs by the used Müller-Gärtner method. However, the negative correlation remained significant also after correction for GM volume of the ipsilateral hippocampal formation, suggesting that it is independent of GM volume. This was further supported by linear regression of the naming animals
Table 2
Partial correlation between pons-scaled, PVE-corrected HippForm-FDG (maximum over both hemispheres) and the different CERAD-Plus subdomains (z-scores adjusted for age, gender, and education) corrected for overall cognitive performance (MMSE z-score), for pons-scaled, PVE-corrected FDG uptake in the AD meta-ROI, or for presence versus absence of clinical Alzheimer’s disease.

<table>
<thead>
<tr>
<th>CERAD-Plus (z-score)</th>
<th>HippForm-FDG corrected for MMSE</th>
<th>HippForm-FDG corrected for AD-FDG</th>
<th>HippForm-FDG corrected for Alzheimer’s disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animals</td>
<td>−0.297</td>
<td>−0.334</td>
<td>−0.321</td>
</tr>
<tr>
<td>p</td>
<td>0.006</td>
<td>0.002</td>
<td>0.003</td>
</tr>
<tr>
<td>Boston Naming Test</td>
<td>−0.084</td>
<td>−0.102</td>
<td>−0.091</td>
</tr>
<tr>
<td>p</td>
<td>0.451</td>
<td>0.359</td>
<td>0.413</td>
</tr>
<tr>
<td>MMSE</td>
<td>−0.417</td>
<td>0.417</td>
<td>0.455</td>
</tr>
<tr>
<td>p</td>
<td>0.132</td>
<td>0.045</td>
<td>0.054</td>
</tr>
<tr>
<td>Learning word list</td>
<td>0.230</td>
<td>0.682</td>
<td>0.626</td>
</tr>
<tr>
<td>p</td>
<td>0.024</td>
<td>0.004</td>
<td>0.018</td>
</tr>
<tr>
<td>Copy figures</td>
<td>0.828</td>
<td>0.969</td>
<td>0.872</td>
</tr>
<tr>
<td>p</td>
<td>0.180</td>
<td>0.129</td>
<td>0.076</td>
</tr>
<tr>
<td>Trail Making Test A</td>
<td>−0.224</td>
<td>−0.264</td>
<td>−0.246</td>
</tr>
<tr>
<td>p</td>
<td>0.079</td>
<td>0.017</td>
<td>0.016</td>
</tr>
<tr>
<td>Trail Making Test B</td>
<td>0.476</td>
<td>0.879</td>
<td>0.885</td>
</tr>
<tr>
<td>p</td>
<td>0.066</td>
<td>0.029</td>
<td>0.043</td>
</tr>
<tr>
<td>S-words</td>
<td>−0.268</td>
<td>−0.314</td>
<td>−0.360</td>
</tr>
<tr>
<td>p</td>
<td>0.186</td>
<td>0.118</td>
<td>0.071</td>
</tr>
<tr>
<td>p</td>
<td>0.015</td>
<td>0.008</td>
<td>0.007</td>
</tr>
</tbody>
</table>

Given are the partial correlation coefficients together with their p-value.
Key: AD, Alzheimer’s disease; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; FDG, 18F-fluorodeoxyglucose; HippForm-FDG, FDG uptake in the hippocampal formation; MMSE, Mini–Mental State Examination; ROI, region of interest.

The present study extends previous findings of Pasquini et al. who reported increased intrinsic functional connectivity of the hippocampus in patients with AD to be associated with more strongly impaired delayed recall (Pasquini et al., 2015). Therapeutic potential was demonstrated by Bakker et al. who used low-dose leviracetam, an antiepileptic drug, to target excess hippocampal activity in patients with amnestic MCI (Bakker et al., 2012). Two weeks of treatment reduced hippocampal activity toward normal values and significantly improved memory function in a three-choice memory task (Bakker et al., 2012). It is important to mention that Bakker et al. characterized hippocampal activity by fMRI measurement of the blood oxygenation level dependent response during a cognitive task designed to assess memory errors (Bakker et al., 2012). The results need not necessarily apply to mesiotemporal hyperactivity in resting state as characterized by glucose metabolism in FDG PET. Considering the risk of unwanted side effects, the therapeutic potential of low-dose leviracetam in patients with cognitive impairment and increased glucose metabolism in the hippocampal formation should be tested in a prospective study before it might be recommended for clinical use.

There is evidence from preclinical studies that tau pathology interferes with the regulation of excitability and synchronization of neuronal networks. Genetic removal of tau decreases hyperexcitability in animal models of epilepsy resulting in reduced interictal spiking and spontaneous seizures (Holth et al., 2013; Roberson et al., 2007), it normalizes inhibitory/excitatory imbalance (Roberson et al., 2007, 2011), and it rescues long-term potentiation alterations in AD mouse models (Shipton et al., 2011). Disruption of GABAergic neuronal networks is one possible mechanism of tau-associated disturbance of excitability of hippocampal neurons (Levenga et al., 2013; Loreth et al., 2012), as the alterations can be associated disturbance of excitability of hippocampal neurons (Levenga et al., 2013; Loreth et al., 2012), as the alterations can be associated disturbance of excitability of hippocampal neurons (Levenga et al., 2013). Further, the lack of significant correlation between glucose metabolism of the hippocampal formation and its functional connectivity to other brain regions in the present study might be explained by the more heterogeneous patient sample, both with respect to the severity of cognitive impairment (ranging from MCI to moderate dementia) and with respect to its etiology: non-neurodegenerative etiology (e.g., reduced general health, depression, and prolonged effect of delirium), AD, CVD, MD, and neurodegenerative etiology other than AD (e.g., Lewy body disease and frontotemporal lobar degeneration). In addition, the patient sample of the present study included a rather large fraction of patients with considerable WM disease that might affect functional connectivity. Scoring of the severity of WM hyperintensity burden by an experienced neuroradiologist had resulted in “mild, normal for age” in 37 patients (42.5%), “moderate, more than expected for age” in 34 patients (39.1%), and “extensive” in 16 patients (18.4%). Furthermore, Tahmasian et al. used an integrated PET/MRI system for simultaneous acquisition of FDG PET and rs-fMRI (Tahmasian et al., 2015). In the present study, PET and rs-fMRI had been performed with 2 different scanners on 2 different days. Although the delay...
between PET and fMRI was rather small (no more than 1 week in 82 of the 87 patients and no more than 1 month in the remaining 5 patients), it might have caused additional variability that reduced the power to detect associations between cerebral glucose metabolism and functional connectivity. Given that spatial overlap and quantitative correlation of FDG uptake and functional connectivity is surprisingly low in many studies (Adriaanse et al., 2016; despite the expected causal relationship between synaptic failure and impaired functional connectivity), this additional variability might have obscured potential associations in the present study. Finally, it is important to mention that acute phase autoimmune encephalitis that can be associated with mesiobial hypermetabolism (limbic encephalitis), particularly in patients with autoantibodies against intracellular antigens (Baumgartner et al., 2013), was very unlikely in the patients of the present study, although chronic phase autoimmune encephalitis is increasingly recognized as possible explanation of clinically uncertain cognitive decline in the elderly (Doss et al., 2014).

In conclusion, the findings of the present study provide evidence that increased glucose metabolism in the hippocampal formation of cognitively impaired patients is a consequence of detrimental adaption rather than a beneficial compensatory reaction. Thus, excess glucose metabolism of the hippocampal formation might be a useful therapeutic target in these patients.

Disclosure statement

The authors have no actual or potential conflicts of interest.

Acknowledgements

Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U01 AG024904 and DOD ADNI; National Institute of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Aracron Biotech; BioClinica, Inc; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc; Janssen Alzheimer Immunotherapy Research & Development, LLC.; company Genentech, Inc; Fujirebio; GE Healthcare; IXICO Ltd.; facilitated by the Foundation for the National Institutes of Health the European Union (reference numbers 10153407, 10153971, 10153458, 10153460, 10153461, 10153462, and 10153463).

References


